Rizatriptan (Maxalt) 10 mg wafers for migraine, and revised listings for other 5HT1 agonists (‘triptans’)
Published in NPS RADAR
Date published: About this date
Rizatriptan 10 mg wafers were listed on the Pharmaceutical Benefits Scheme (PBS) as authority required (streamlined) on 1 March 2010 for people with past migraines that have usually failed to respond to analgesics.1
As of 1 April 2010, the PBS restriction for naratriptan, sumatriptan and zolmitriptan has changed: there is no longer a requirement for past migraines to have failed to respond to ergotamine*.6 This change brings the restriction into line with that of rizatriptan.
* Injectable dihydroergotamine is the only ergot alkaloid indicated for migraine listed on the PBS
- Pharmaceutical Benefits Advisory Committee. Positive recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in November 2009 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS). Canberra: Australian Government Department of Health and Ageing, 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-nov09-positive (accessed 6 January 2010).
- Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache 2009;49:S3–20.
- Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633–58.
- Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007;47:1152–68.
- National Prescribing Centre. The management of migraine. MeReC Bulletin 13:(2). Liverpool: National Health Service, 2002. http://www.npc.co.uk/ebt/merec/pain/migraine/resources/merec_bulletin_vol13_no2.pdf (accessed 15 January 2010).
- Department of Health and Ageing. PBS for Health Professionals. Canberra, 2010. www.pbs.gov.au (accessed 6 January 2010).